Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion description "[Given that GTA has been chronically administered safely to infants with Canavan disease, a leukodystrophy due to ASPA mutation, GTA-mediated acetate supplementation may provide a novel, safe chemotherapeutic adjuvant to reduce the growth of glioma tumors, most notably the more rapidly proliferating, glycolytic and hypoacetylated mesenchymal glioma tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion evidence source_evidence_literature NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion SIO_000772 23996800 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion wasDerivedFrom befree-20150227 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_assertion wasGeneratedBy ECO_0000203 NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.
- befree-20150227 importedOn "2015-02-27" NP516409.RASkeRNOLDJDiEupccoK_KEc_S4eMPvip6dOAMwVqeeCM130_provenance.